Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with
solvent-based taxanes as first-line treatment for patients with advanced primary epithelial
ovarian cancer (EOC), primary peritoneal carcinoma or fallopian tube carcinoma.
Phase:
Phase 3
Details
Lead Sponsor:
Women's Hospital School Of Medicine Zhejiang University
Collaborators:
First Affiliated Hospital of Wenzhou Medical University Jiaxing Maternity and Child Health Care Hospital Ningbo No. 1 Hospital Ningbo Women & Children's Hospital Qilu Hospital of Shandong University Second Affiliated Hospital of Wenzhou Medical University Second Affiliated Hospital, School of Medicine, Zhejiang University Sir Run Run Shaw Hospital Sun Yat-sen University Zhejiang University